Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.

Riley MM, San P, Lok E, Swanson KD, Wong ET.

J Vis Exp. 2019 Apr 16;(146). doi: 10.3791/58937.

PMID:
31058901
2.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

3.

Tumor treating fields increases membrane permeability in glioblastoma cells.

Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS.

Cell Death Discov. 2018 Dec 5;4:113. doi: 10.1038/s41420-018-0130-x. eCollection 2018.

4.

What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?

Ornelas AS, Porter AB, Sharma A, Knox MG, Marks LA, Wingerchuk DM, O'Carroll CB.

Neurologist. 2019 Mar;24(2):71-73. doi: 10.1097/NRL.0000000000000222.

PMID:
30817495
5.

Tumor treating fields: a new standard treatment for glioblastoma?

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Opin Neurol. 2015 Dec;28(6):659-64. doi: 10.1097/WCO.0000000000000250. Review.

PMID:
26551239
6.

Tumor treating fields: a new frontier in cancer therapy.

Davies AM, Weinberg U, Palti Y.

Ann N Y Acad Sci. 2013 Jul;1291:86-95. doi: 10.1111/nyas.12112. Epub 2013 May 9. Review.

PMID:
23659608
7.

Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab.

Elzinga G, Wong ET.

Case Rep Neurol. 2014 Apr 5;6(1):109-15. doi: 10.1159/000362264. eCollection 2014 Jan.

8.

Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.

Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N.

BMC Cancer. 2016 Nov 4;16(1):842.

9.

A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.

Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR.

IEEE Rev Biomed Eng. 2018;11:195-207. doi: 10.1109/RBME.2017.2765282. Epub 2018 Feb 13. Review.

PMID:
29993870
10.

Tumor treating fields: concept, evidence and future.

Pless M, Weinberg U.

Expert Opin Investig Drugs. 2011 Aug;20(8):1099-106. doi: 10.1517/13543784.2011.583236. Epub 2011 May 9. Review.

PMID:
21548832
11.

Tumour treating fields in a combinational therapeutic approach.

Branter J, Basu S, Smith S.

Oncotarget. 2018 Nov 27;9(93):36631-36644. doi: 10.18632/oncotarget.26344. eCollection 2018 Nov 27. Review.

12.

An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas.

Wong ET, Lok E, Swanson KD.

Curr Treat Options Oncol. 2015 Aug;16(8):40. doi: 10.1007/s11864-015-0353-5. Review.

13.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

14.

Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.

Kesari S, Ram Z; EF-14 Trial Investigators.

CNS Oncol. 2017 Jul;6(3):185-193. doi: 10.2217/cns-2016-0049. Epub 2017 Apr 12.

15.

Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy.

Li T, Shukla G, Peng C, Lockamy V, Liu H, Shi W.

Front Oncol. 2018 Mar 13;8:51. doi: 10.3389/fonc.2018.00051. eCollection 2018.

16.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

17.

Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.

Saria MG, Kesari S.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S9-S13. doi: 10.1188/16.CJON.S1.9-13. Review.

18.

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.

Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, Baek JH, Kim JY, Hwang SG, Yoon M.

Int J Mol Sci. 2018 Nov 21;19(11). pii: E3684. doi: 10.3390/ijms19113684.

19.

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.

Toms SA, Kim CY, Nicholas G, Ram Z.

J Neurooncol. 2019 Jan;141(2):467-473. doi: 10.1007/s11060-018-03057-z. Epub 2018 Dec 1.

20.

Rationale and Background on Tumor-Treating Fields for Glioblastoma.

Schwartz MA, Onuselogu L.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S20-4. doi: 10.1188/16.CJON.S1.20-24.

Supplemental Content

Support Center